Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892968 | 1.00 | CHRNB4 (0.43) | CHRNB4CHRNA3NPY5RSLC6A9CYP2D6 | |
| SCHEMBL18473157 | 1.00 | CHRNB4 (0.43) | CHRNB4CHRNA3NPY5RSLC6A9CYP2D6 | |
| SCHEMBL24736540 | 1.00 | CHRNB4 (0.43) | CHRNB4CHRNA3NPY5RSLC6A9CYP2D6 | |
| SCHEMBL9892960 | 0.88 | NPY5R (0.39) | NPY5RCYP2D6 | |
| SCHEMBL21315594 | 0.88 | NPY5R (0.39) | NPY5RCYP2D6 | |
| SCHEMBL17555699 | 0.88 | NPY5R (0.39) | NPY5RCYP2D6 | |
| SCHEMBL25130480 | 0.88 | NPY5R (0.39) | NPY5RCYP2D6 | |
| SCHEMBL14957030 | 0.88 | NPY5R (0.39) | NPY5RCYP2D6 | |
| SCHEMBL14957031 | 0.88 | NPY5R (0.39) | NPY5RCYP2D6 | |
| SCHEMBL22915321 | 0.88 | CHRNB4 (0.40) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088378-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENETECH INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | CHRNB4 2590/4885CHRNA3 2489/4885NPY5R 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.